GLP1R and hydrops fetalis: The results of this study advocates the need for larger randomized, placebo – controlled studies with GLP1-RA in obese patients with HFpEF to assess (confirm) their ability to reduce clinical HF-related events (such as cardiovascular mortality and HF-related hospitalizations).